NCT02363439View on ClinicalTrials.gov

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly

IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401

Sponsors
All Listed Sponsors
lead

Idera Pharmaceuticals, Inc.

INDUSTRY

NCT02363439 - Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 | Biotech Hunter | Biotech Hunter